DE3853422T2 - HIV-3-Retrovirus und seine Verwendung. - Google Patents

HIV-3-Retrovirus und seine Verwendung.

Info

Publication number
DE3853422T2
DE3853422T2 DE3853422T DE3853422T DE3853422T2 DE 3853422 T2 DE3853422 T2 DE 3853422T2 DE 3853422 T DE3853422 T DE 3853422T DE 3853422 T DE3853422 T DE 3853422T DE 3853422 T2 DE3853422 T2 DE 3853422T2
Authority
DE
Germany
Prior art keywords
hiv
retrovirus
nucleic acid
acid sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3853422T
Other languages
English (en)
Other versions
DE3853422D1 (de
Inventor
Leys Robert De
Bart Vanderborght
Eric Saman
Heuverswijn Hugo Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8199044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3853422(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of DE3853422D1 publication Critical patent/DE3853422D1/de
Application granted granted Critical
Publication of DE3853422T2 publication Critical patent/DE3853422T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
DE3853422T 1988-06-09 1988-06-09 HIV-3-Retrovirus und seine Verwendung. Expired - Lifetime DE3853422T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88109200A EP0345375B1 (de) 1988-06-09 1988-06-09 HIV-3-Retrovirus und seine Verwendung

Publications (2)

Publication Number Publication Date
DE3853422D1 DE3853422D1 (de) 1995-04-27
DE3853422T2 true DE3853422T2 (de) 1995-10-26

Family

ID=8199044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3853422T Expired - Lifetime DE3853422T2 (de) 1988-06-09 1988-06-09 HIV-3-Retrovirus und seine Verwendung.

Country Status (10)

Country Link
US (7) US5304466A (de)
EP (3) EP1369427A3 (de)
JP (1) JP2882654B2 (de)
AT (1) ATE120234T1 (de)
AU (1) AU625970B2 (de)
CY (1) CY2051B1 (de)
DE (1) DE3853422T2 (de)
DK (1) DK176078B1 (de)
ES (1) ES2072853T3 (de)
WO (1) WO1989012094A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364933A (en) 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
EP1369427A3 (de) * 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 Retrovirusstammen und ihre Verwendung
ES2053014T5 (es) * 1990-06-15 2001-02-16 Innogenetics Nv El retrovirus sivcpz-ant y sus usos.
ES2133392T5 (es) * 1992-03-06 2004-12-16 N.V. Innogenetics S.A. Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico.
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
ES2126620T5 (es) * 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
ATE374253T1 (de) 1994-10-20 2007-10-15 Pasteur Institut Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
JP3889045B2 (ja) * 1995-06-07 2007-03-07 アボツト・ラボラトリーズ Ｈｉｖを検出するためのペプチド
US5612473A (en) * 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US6593079B1 (en) † 1997-03-10 2003-07-15 Roche Diagnostics Gmbh Method for simultaneous detection of HIV antigens and HIV antibodies
US6846905B2 (en) * 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
US7244570B2 (en) 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
JP4824236B2 (ja) 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
AU784635B2 (en) 1999-11-16 2006-05-18 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003098215A1 (en) * 2002-05-16 2003-11-27 Medmira Inc. Rapid vaccinia antibody detection device, method and test kit
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
DK2211873T3 (da) 2007-10-22 2012-11-19 Amorphical Ltd Stabil, amorf calciumcarbonat, der omfatter phosphorylerede aminosyrer
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10758565B2 (en) 2015-06-04 2020-09-01 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
IL294615A (en) 2016-10-25 2022-09-01 Amorphical Ltd Amorphous calcium carbonate for the treatment of leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217861A (en) * 1983-09-15 1993-06-08 Institut Pasteur Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor
ATE373010T1 (de) * 1984-10-18 2007-09-15 Pasteur Institut Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen
US5066782A (en) * 1986-01-22 1991-11-19 Institut Pasteur Retrovirus capable of causing AIDS, means and method for detecting it in vitro
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
OA08468A (fr) * 1986-01-22 1988-07-29 Pasteur Institut Retrovirus du type HIV-2 susceptible de provoquer le SIDA et ses constituants antigéniques et nucléiques.
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
EP1369427A3 (de) * 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 Retrovirusstammen und ihre Verwendung

Also Published As

Publication number Publication date
CY2051B1 (en) 1998-04-30
US5304466A (en) 1994-04-19
EP0345375B1 (de) 1995-03-22
EP0657532A1 (de) 1995-06-14
DK176078B1 (da) 2006-04-10
EP0657532B1 (de) 2003-12-17
US5858647A (en) 1999-01-12
EP0345375A1 (de) 1989-12-13
WO1989012094A1 (en) 1989-12-14
US5567603A (en) 1996-10-22
JP2882654B2 (ja) 1999-04-12
DK33190D0 (da) 1990-02-08
DE3853422D1 (de) 1995-04-27
DK33190A (da) 1990-03-28
US6013484A (en) 2000-01-11
US20030039954A1 (en) 2003-02-27
AU625970B2 (en) 1992-07-23
ES2072853T3 (es) 1995-08-01
JPH02504583A (ja) 1990-12-27
EP1369427A3 (de) 2004-05-12
US5795743A (en) 1998-08-18
EP1369427A2 (de) 2003-12-10
US6265200B1 (en) 2001-07-24
AU3762889A (en) 1990-01-05
ATE120234T1 (de) 1995-04-15

Similar Documents

Publication Publication Date Title
DE3853422D1 (de) HIV-3-Retrovirus und seine Verwendung.
Cafaro et al. Control of SHIV-89.6 P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
Salminen et al. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
CA2009403C (en) A packaging defective hiv provirus, cell lines, and uses thereof
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
NO874750L (no) Bestemte dna-sekvenser avledet fra et papillomavirusgenom, deres bruk i in vitro diagnostikk og produksjon av antigene preparater.
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
CA2107732A1 (en) Retrovirus from the hiv group and its use
EP0512017A1 (de) Vakzine.
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
EP0608261A4 (de) Zusammensetzung aus einem immunreaktiven hepatitis-c-virus-polypeptid.
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
KR950032278A (ko) 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도
DE60026199T2 (de) Synthetische Gene für gagpol und deren Verwendungen
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
Etemad-Moghadam et al. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys
Hejdeman et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy
KR900702045A (ko) 천연 hiv gp 160의 제조방법
Bibollet-Ruche et al. Complete genome analysis of one of the earliest SIVcpz Ptt strains from Gabon (SIVcpzGAB2)
EP0315459A2 (de) Umvollständige HIV-Partikel und Verfahren zu ihrer Herstellung
CA2408786A1 (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
DK0592636T3 (da) Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition